Bayer Schering Pharma sees sales growth in third quarter
29 October 2010 00:00 in Pharmaceutical Company Financials
Bayer Schering Pharma has seen a year-on-year sales increase in the third quarter of 2010, according to the Bayer group's latest financial report.
Fiscal statistics for the three-month period showed that pharmaceutical sales generated 2.7 billion euros (1.7 billion pounds) for the firm, up by 7.2 percent compared to Q3 2009.
Among the specific products to see strong sales during the quarter were the hormone-releasing intrauterine device Mirena, haemophilia drug Kogenate and erectile dysfunction treatment Levitra, while emerging market performance saw a major improvement.
Meanwhile, sales across the entire Bayer HealthCare division increased by 8.5 percent year-on-year, helping the group as a whole to generate a total figure of 8.6 billion euros.
Dr Marijn Dekkers, management board chairman at Bayer, said: "We are pleased that our third-quarter results showed an improvement on last year and we remain confident for the full year 2010."
Earlier this month, Bayer Schering Pharma published positive data from a clinical trial of Betaferon, its therapy for multiple sclerosis.
Other news stories from 29/10/2010
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency